Press Releases

Date	Title	Company
05-Jun-2023	Special Purpose Needles Market in China is expected to grow at 8.3% CAGR during the forecast period 2022 to 2032	MARKITWIRED
05-Jun-2023	Regenerative Medicine Market \| 3M, Allergan plc, Amgen, Inc., Aspect Biosystems \| By 2032	MARKITWIRED
05-Jun-2023	Saudi Arabia Pharmaceutical Market is expected to flourish US$ 13,000 Million by 2032 at a CAGR of 9%	MARKITWIRED
05-Jun-2023	Antibodies Market is likely to be around US$ 834.2 Billion grow at a CAGR of 13.4% through 2033	MARKITWIRED
05-Jun-2023	BrainChip and Lorser Industries to Develop Neuromorphic Computing Systems for Software-Defined Radio Devices	Businesswire
04-Jun-2023	Reigniting the Cancer Moonshot: Massive Bio Joins CancerX as Founding Member to Accelerate Innovation and AI Implementation in Cancer Care	Businesswire
04-Jun-2023	Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting	Businesswire
04-Jun-2023	Nucleai and Mayo Clinic BioPharma Diagnostics Announce Strategic Collaboration to Transform Digital Pathology for Drug Development and Clinical Practice	Businesswire
04-Jun-2023	Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer	Businesswire
03-Jun-2023	Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study	Businesswire
03-Jun-2023	Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study	Businesswire
03-Jun-2023	Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of SentinelOne, Inc. (S) on Behalf of Investors	Businesswire
03-Jun-2023	Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC	Businesswire
03-Jun-2023	Massive Bio and The Oncology Institute (TOI) Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research	Businesswire
03-Jun-2023	KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma	Businesswire
03-Jun-2023	Rapid Dose Announces Proposed Private Placement Financing	Businesswire
02-Jun-2023	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	Businesswire
02-Jun-2023	Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023	Businesswire
02-Jun-2023	Prothena to Participate in Jefferies 2023 Healthcare Conference	Businesswire
02-Jun-2023	Legend Biotech Announces Participation in Upcoming Investor Conferences	Businesswire